In addition to developing its own medical devices, Critical Innovations assists other companies in developing their technologies and intellectual property targeted toward the combat and emergency environments. This can include the full cycle of medical technology planning, analysis, design, implementation, testing, and deployment. Critical Innovations' value-added expertise includes the provision of clinical subject matter expert feedback, assistance with securing non-dilutional funding, and various business development activities (e.g. transition and commercialization, market analysis, reimbursement analysis, cost analysis).
Nanostasis™ Intravenous Agent for Traumatic Hemorrhage Control
Critical Innovations has been selected for a Phase II U.S. Army Phase II SBIR award to assist subcontractor Cayuga Biotech develop their traumatic hemorrhage treatment technology. Nanostasis™ is a novel systemic therapy for out-of-hospital management of combat-associated, non-compressible traumatic hemorrhage starting at the point-of-injury through en route care and beyond. Its novel platelet-like nanoparticles are an ideal intravenous treatment to halt hemorrhage in the far forward combat environment. The final product will not only have innovative hemorrhage-stopping properties, but also be easily transportable (e.g. small volume, no special storage requirements, shelf-stable for long periods under environmental extremes) and easily administered in the operational environment with a straightforward plan for practical combat deployment.
Machine Learning & Medical Predictive Algorithm for Medical Applications on End User Devices (PAL-Medic)
Critical Innovations is assisting Perceptronics Solutions as a subcontractor on this SBIR Phase II program from the US Army Research, Development and Engineering Command (RDECOM). This technology is an integrated mobile application that will provide critical support to Army combat medics and civilian paramedics during out-of-hospital patient care, while additionally enhancing the subsequent care process. It includes the application of advanced AI-based machine learning algorithms in combination with available procedural and medical databases to provide medics with instantaneous medical alerts, predictions of patient condition, applicable care guidelines, and recommended medical courses of action. The system will run on both US Army PEO Soldier NETT Warrior Android/End User Devices and commercial systems.
- CAUTION -
All medical technologies listed on this page are INVESTIGATIONAL and NOT AVAILABLE FOR COMMERCIAL SALE. These statements have NOT been evaluated by the Food and Drug Administration and these technologies are NOT currently approved for human use.
CD010 Rev.E 12-16-19